Your session is about to expire
← Back to Search
Phase 1: Dose Escalation for Pembrolizumab and Difluoromethylornithine (DFMO) for Lung Cancer
Study Summary
This trial aims to test the safety and effectiveness of a drug called Difluoromethylornithine (DFMO) when used in combination with pembrolizumab for the treatment of
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What is the current number of participants enrolled in this clinical study?
"Indeed, the data available on clinicaltrials.gov indicates that this ongoing clinical trial is actively seeking eligible participants. The study was initially posted on January 12th, 2024 and most recently updated on the same day. Currently, there are openings for a total of 45 individuals at one designated site."
Is the recruitment phase of this clinical trial still ongoing?
"Indeed, according to the information provided on clinicaltrials.gov, this investigation is currently in the recruitment phase. The trial was initially made available on January 12th, 2024 and received its most recent update on the same date."
Share this study with friends
Copy Link
Messenger